Ventripoint Diagnostics Ltd (CVE:VPT) (OTCQB:VPTDF) announced Tuesday that the development stage for its next-generation VMS +3.0 heart-monitoring system is nearing completion.
Usability studies are now underway at a pair of leading Canadian hospitals to establish the effectiveness and ease of use of VMS +3.0 and the Toronto-based company will seek regulatory approval in North America and Europe as soon as these studies are finished.
VMS is a machine, which revolutionizes the way doctors treat heart patients as it can give accurate and rapid volumetric information about all four chambers of the heart.
It is the only technology in the world that can perform such an analysis of all four chambers using data from a conventional 2D (two dimensional) eco-cardiogram (in other words an ultrasound test).
Ventripoint's latest system uses sensor technology, which allows for patients to move during the imaging portion of the exam, and it is compact and portable enough that it can be set up within minutes.
“Replacing the old magnetic tracking system with our new tracking sensor technology enables patient repositioning during the examination,” said George Adams, CEO of Ventripoint. “This feature eliminates the usual restrictions on the person being scanned and will be instrumental in the ease of use by clinicians for both children and adults.”
Ventripoint is also developing a workstation version of the VMS + 3.0 software, which allows for the analysis of echocardiograms in a reading room elsewhere in the hospital. This will permit sonographers to continue to scan new patients, while studies are analyzed by cardiologists.
Ventripoint shares held steady at C$0.16 in morning trade on Tuesday.
Contact Ellen Kelleher at [email protected]